KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:KMPH
- CUSIP: N/A
- Web: www.kempharm.com
Capitalization:- Market Cap: $49.07 million
- Outstanding Shares: 14,648,000
Average Prices:- 50 Day Moving Avg: $4.02
- 200 Day Moving Avg: $3.91
- 52 Week Range: $2.90 - $5.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.74
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($2.32) per share
- Price / Book: -1.47
Profitability:- EBIDTA: ($34,650,000.00)
- Return on Assets: -28.72%
Debt:- Debt-to-Equity Ratio: -2.70%
- Current Ratio: 13.13%
- Quick Ratio: 13.13%
Misc:- Average Volume: 29,378 shs.
- Beta: -1.23
- Short Ratio: 30.25
Frequently Asked Questions for KemPharm (NASDAQ:KMPH)
What is KemPharm's stock symbol?
KemPharm trades on the NASDAQ under the ticker symbol "KMPH."
How were KemPharm's earnings last quarter?
KemPharm, Inc. (NASDAQ:KMPH) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.21. View KemPharm's Earnings History.
Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?
3 analysts have issued twelve-month price targets for KemPharm's stock. Their forecasts range from $7.00 to $13.00. On average, they anticipate KemPharm's stock price to reach $9.33 in the next year. View Analyst Ratings for KemPharm.
Who are some of KemPharm's key competitors?
Some companies that are related to KemPharm include AcelRx Pharmaceuticals (ACRX), Affimed N.V. (AFMD), Verastem (VSTM), MEI Pharma (MEIP), Flex Pharma (FLKS), Lipocine (LPCN), Ergomed PLC (ERGO), Nexvet Biopharma PLC (NVET), Rexahn Pharmaceuticals (RNN), Synthetic Biologics (SYN), pSivida Corp. (PSDV), Xenon Pharmaceuticals (XENE), Galmed Pharmaceuticals (GLMD), Actinium Pharmaceuticals (ATNM), ImmuPharma PLC (IMM), Imprimis Pharmaceuticals (IMMY), Dicerna Pharmaceuticals (DRNA) and Aldeyra Therapeutics (ALDX).
Who are KemPharm's key executives?
KemPharm's management team includes the folowing people:
- Travis C. Mickle Ph.D., Chairman of the Board, President, Chief Executive Officer
- Timothy J. Sangiovanni, Principal Accounting Officer, Vice President, Corporate Controller
- Gordon K. Johnson, Chief Business Officer
When did KemPharm IPO?
(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.
Who owns KemPharm stock?
KemPharm's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Arete Wealth Advisors LLC (5.81%), Creative Planning (3.10%), Vanguard Group Inc. (2.05%), C WorldWide Group Holding A S (1.24%), Victory Capital Management Inc. (0.90%) and Parkwood LLC (0.86%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.
Who sold KemPharm stock? Who is selling KemPharm stock?
Who bought KemPharm stock? Who is buying KemPharm stock?
KemPharm's stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley, C WorldWide Group Holding A S, Creative Planning, Bank of New York Mellon Corp, Arete Wealth Advisors LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.
How do I buy KemPharm stock?
Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is KemPharm's stock price today?
One share of KemPharm stock can currently be purchased for approximately $3.40.
MarketBeat Community Rating for KemPharm (NASDAQ KMPH)MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for KemPharm (NASDAQ:KMPH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $9.33 (174.51% upside) |
Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/15/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $8.00 | Medium |  |
| 5/10/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $13.00 | Low | |
| 3/12/2017 | Canaccord Genuity | Set Price Target | Buy | $7.00 | High | |
| 8/15/2015 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
(Data available from 6/27/2015 forward)
Earnings History for KemPharm (NASDAQ:KMPH)Earnings History by Quarter for KemPharm (NASDAQ KMPH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.63) | ($0.84) | | | View | N/A | |
| 3/9/2017 | Q4 2016 | ($0.70) | ($0.68) | | | View | Listen | |
| 11/9/2016 | Q3 2016 | ($0.70) | ($0.92) | | | View | Listen | |
| 8/10/2016 | Q2 | ($0.94) | ($0.58) | | | View | Listen | |
| 5/12/2016 | Q1 | ($0.56) | ($0.20) | | | View | Listen | |
| 3/10/2016 | Q4 | ($0.50) | ($0.64) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.48) | ($0.68) | | | View | Listen | |
| 8/13/2015 | Q215 | ($0.47) | ($0.59) | | | View | Listen | |
| 5/27/2015 | Q1 | ($0.49) | ($2.50) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for KemPharm (NASDAQ:KMPH)2017 EPS Consensus Estimate: ($2.78)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.69) | ($0.69) | ($0.69) |
| Q2 2017 | 1 | ($0.63) | ($0.63) | ($0.63) |
| Q3 2017 | 1 | ($0.66) | ($0.66) | ($0.66) |
| Q4 2017 | 1 | ($0.80) | ($0.80) | ($0.80) |
(Data provided by Zacks Investment Research)
Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for KemPharm (NASDAQ:KMPH)Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 42.11%
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/20/2017 | Travis C Mickle | CEO | Buy | 8,000 | $3.45 | $27,600.00 | |
| 6/19/2017 | R. Laduane Clifton | CFO | Buy | 275 | $3.30 | $907.50 | |
| 5/25/2017 | Daniel L Cohen | EVP | Buy | 2,500 | $4.11 | $10,275.00 | |
| 3/31/2017 | Daniel L Cohen | EVP | Buy | 2,500 | $4.48 | $11,200.00 | |
| 3/24/2017 | R. Laduane Clifton | CFO | Buy | 1,000 | $4.24 | $4,240.00 | |
| 3/22/2017 | Travis C Mickle | CEO | Buy | 2,000 | $4.10 | $8,200.00 | |
| 3/20/2017 | David S Tierney | Director | Buy | 1,000 | $4.20 | $4,200.00 | |
| 11/30/2016 | Daniel L Cohen | EVP | Buy | 5,000 | $3.50 | $17,500.00 | |
| 9/6/2016 | Daniel L Cohen | EVP | Buy | 10,000 | $4.75 | $47,500.00 | |
| 8/17/2016 | Travis C Mickle | CEO | Buy | 5,000 | $4.95 | $24,750.00 | |
| 3/29/2016 | Travis C Mickle | CEO | Buy | 2,450 | $14.57 | $35,696.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for KemPharm (NASDAQ:KMPH)
Latest Headlines for KemPharm (NASDAQ:KMPH)
| Source: |
|
| Date | Headline |
|---|
 | KemPharm (KMPH) Granted First Patent for KP746
www.streetinsider.com - June 26 at 8:05 PM |
 | KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone
finance.yahoo.com - June 26 at 8:05 PM |
 | KemPharm, Inc. (KMPH) CEO Buys $27,600.00 in Stock
www.americanbankingnews.com - June 21 at 1:25 PM |
| KemPharm, Inc. (KMPH) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - June 15 at 6:28 PM |
| KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids
finance.yahoo.com - June 9 at 9:20 AM |
| KemPharm Announces Addition to Leadership Team
finance.yahoo.com - June 1 at 7:51 AM |
| KemPharm Inc (KMPH) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 28 at 5:56 PM |
| Daniel L. Cohen Purchases 2,500 Shares of KemPharm Inc (KMPH) Stock
www.americanbankingnews.com - May 26 at 8:29 PM |
| Q2 2017 EPS Estimates for KemPharm Inc Reduced by Oppenheimer Holdings (KMPH)
www.americanbankingnews.com - May 15 at 7:46 AM |
| FY2021 EPS Estimates for KemPharm Inc (KMPH) Cut by Analyst
www.americanbankingnews.com - May 12 at 6:56 PM |
| KemPharm Inc (KMPH) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 7:36 PM |
| KemPharm Inc (KMPH) Given a $13.00 Price Target by Oppenheimer Holdings Inc. Analysts
www.americanbankingnews.com - May 11 at 2:56 PM |
 | KemPharma reports 1Q loss
www.cnbc.com - May 10 at 6:06 PM |
| KemPharm, Inc. Reports First Quarter 2017 Results
finance.yahoo.com - May 10 at 6:06 PM |
| Investor Network: KemPharm, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 1:04 PM |
| KemPharm Inc (KMPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 5 at 12:46 AM |
| KemPharm (KMPH) Receiving Somewhat Favorable Press Coverage, Report Finds
www.americanbankingnews.com - May 4 at 2:18 PM |
| KemPharm Inc (KMPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 4 at 1:17 AM |
| Zacks Investment Research Downgrades KemPharm Inc (KMPH) to Hold
www.americanbankingnews.com - May 4 at 1:16 AM |
| KemPharm (KMPH) Getting Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - May 1 at 3:42 PM |
| KemPharm, Inc. to Report First Quarter 2017 Results
finance.yahoo.com - May 1 at 1:00 PM |
| Zacks: Analysts Expect KemPharm Inc (KMPH) to Announce -$0.61 Earnings Per Share
www.americanbankingnews.com - April 27 at 11:20 PM |
| KemPharm (KMPH) Receives News Sentiment Rating of 0.31
www.americanbankingnews.com - April 20 at 11:49 PM |
| KemPharm (KMPH) Earns News Impact Score of 0.31
www.americanbankingnews.com - April 17 at 9:10 AM |
| KemPharm Inc (KMPH) Given a $8.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - April 13 at 6:14 PM |
| KemPharm (KMPH) Earning Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 13 at 3:18 PM |
| KemPharm Inc (KMPH) Expected to Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 8 at 9:07 AM |
| -$0.61 EPS Expected for KemPharm Inc (KMPH) This Quarter
www.americanbankingnews.com - April 6 at 6:18 PM |
| Brokerages Set $27.33 Target Price for KemPharm Inc (KMPH)
www.americanbankingnews.com - April 4 at 12:43 AM |
| Zacks Investment Research Upgrades KemPharm Inc (KMPH) to "Hold"
www.americanbankingnews.com - April 2 at 9:55 AM |
| KEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
biz.yahoo.com - March 28 at 5:46 PM |
| KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
finance.yahoo.com - March 27 at 10:43 AM |
| KemPharm Inc (KMPH) Stock Rating Reaffirmed by Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 24 at 11:04 PM |
 | KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
us.rd.yahoo.com - March 16 at 6:58 PM |
| 7:32 am KemPharm presents data on KP511 and KP201/IR at the American Academy of Pain Medicine Annual Meeting
us.rd.yahoo.com - March 16 at 6:58 PM |
| KEMPHARM, INC Financials
finance.yahoo.com - March 16 at 6:58 PM |
| Can The Uptrend Continue for KemPharm (KMPH)?
finance.yahoo.com - March 15 at 6:27 PM |
| KemPharm Inc (KMPH) Upgraded by Zacks Investment Research to “Buy”
www.americanbankingnews.com - March 15 at 12:24 AM |
| Oppenheimer Holdings Comments on KemPharm Inc’s FY2021 Earnings (KMPH)
www.americanbankingnews.com - March 13 at 2:48 PM |
| KEMPHARM, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 7:23 PM |
 | KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - GlobeNewswire (press release)
globenewswire.com - March 10 at 7:57 AM |
| KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 9 at 9:06 PM |
| Q4 2016 KemPharm Inc Earnings Release - After Market Close
biz.yahoo.com - March 9 at 8:48 AM |
| KemPharm Inc (KMPH) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 8 at 9:19 AM |
| KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results
finance.yahoo.com - February 28 at 9:37 AM |
| 7:31 am KemPharm announces issuance of two new patents by the USPTO, one related to the KP511 family of compounds and another related to KP201
finance.yahoo.com - February 23 at 6:09 PM |
| KEMPHARM, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 5:50 PM |
| KemPharm to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 7:27 PM |
 | SHAREHOLDER ALERT: Goldberg Law PC Announces an ... - Business Wire (press release)
www.businesswire.com - February 4 at 4:53 AM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - February 3 at 11:52 PM |
KemPharm (KMPH) Chart for Tuesday, June, 27, 2017
